loading...| Preferred Name |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses |
|
| Synonyms |
|
|
| ID |
http://purl.bioontology.org/ontology/HCPCS/M0241 |
|
| cui |
C5574591 |
|
| HAC |
N=No maintenance for this code |
|
| HAD |
20210730 |
|
| HAQ |
0 |
|
| HBT |
O1G=Immunizations/Vaccinations |
|
| HCC |
C=Carrier judgment |
|
| HCD |
20210730 |
|
| HMP |
A=Not applicable as HCPCS priced under one methodology |
|
| HPI |
54=Vaccinations |
|
| HTS |
V=Pneumococcal/flu vaccine (eff 01/96), Pneumococcal/flu/hepatitis B vaccine (eff 04/95-12/95), Pneumococcal only before 04/95 |
|
| notation |
M0241 |
|
| prefLabel |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses |
|
| tui |
T061 |
|
| subClassOf |
http://purl.bioontology.org/ontology/HCPCS/Level%201%3A%20M0000-M1210 |